Modality
Gene Editing
MOA
BETi
Target
FXIa
Pathway
Lipid Met
Pancreatic Ca
Development Pipeline
Preclinical
~Jul 2014
→ ~Oct 2015
Phase 1
~Jan 2016
→ ~Apr 2017
Phase 2
~Jul 2017
→ ~Oct 2018
Phase 3
~Jan 2019
→ ~Apr 2020
NDA/BLA
Jul 2020
→ Feb 2030
NDA/BLACurrent
NCT08875288
1,365 pts·Pancreatic Ca
2020-07→2030-02·Recruiting
NCT06501127
2,048 pts·Pancreatic Ca
2021-05→2029-08·Terminated
3,413 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-08-153.4y awayPh3 Readout· Pancreatic Ca
2030-02-193.9y awayPh3 Readout· Pancreatic Ca
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
NDA/BLA
Recruit…
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2029-08-15 · 3.4y away
Pancreatic Ca
Ph3 Readout
2030-02-19 · 3.9y away
Pancreatic Ca
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08875288 | NDA/BLA | Pancreatic Ca | Recruiting | 1365 | CR |
| NCT06501127 | NDA/BLA | Pancreatic Ca | Terminated | 2048 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| BAY-8733 | Bayer | Preclinical | AuroraA | |
| Rimaosocimab | Amgen | Preclinical | FXIa |